Staff change – Alligator Bioscience

2024-12-02

Regulatory

Alligator sharpens focus on mitazalimab and announces cost reduction program to maximize long-term value creation

Sharpening focus on preparing mitazalimab for Phase 3 and continuing partnering discussions Planned reduction of workforce, mainly wit ...

2024-06-14

Regulatory

Lund, Sweden, June 14, 2024 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the appointment of Johan Giléus as ...

2024-02-082024-02-14

Regulatory

Expected annual cash savings of SEK 20 million Restructuring follows successful conclusion of resource intensive OPTIMIZE-1 Phase 2 trial Fo ...

2023-07-05

Alligator Bioscience AB (publ) today announces that Anette Sundstedt, PhD, Principal Scientist at Alligator, has been appointed as employee ...

2023-03-10

Alligator Bioscience AB (publ) today announces that Tova Landström, PhD, Medical Science Director at Alligator, has been appointed as employ ...

2023-02-14

Laura von Schantz, employee representative, has resigned from the Alligator Bioscience AB Board of Directors, effective February 14, 2023, f ...

2023-02-13

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the promotion of Laura von Schantz to Chief Technology O ...

2022-05-09

Lund, Sweden, May 9, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the appointment of Staffan Encrantz and Den ...

2022-02-01

Lund, Sweden, February 1, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) Alligator Bioscience (Nasdaq Stockholm: ATORX), today announ ...